Since gastric cancer with the MSI-H subtype and PD-L1 positive expression more effectively responds to immune checkpoint inhibitors (ICIs), the expression of ARID1A may become a biomarker for GC immunotherapy [51]. This evidence concerns the gene ARID1A and gastric cancer.